CLARENCE, N.Y.--(BUSINESS WIRE)--November 5, 2009--Greatbatch, Inc. (NYSE:GB), today announced results for its third quarter ended October 2, 2009:

(Dollars in thousands, except share data)	2009 3rd Qtr.			2008 3rd Qtr.			% Change		2009 2nd Qtr.			% Change
Revenue	$	121,470		$	136,242		-11	%	$	134,725		-10	%
GAAP Operating Income (Loss)	$	(23,933	)	$	15,714		NA		$	12,469		NA
GAAP Operating Income (Loss) as % of Sales*		-19.7	%		11.5	%				9.3	%
Adjusted Operating Income*	$	13,646		$	19,279		-29	%	$	14,893		-8	%
Adjusted Operating Income as % of Sales		11.2	%		14.2	%				11.1	%
GAAP Diluted EPS	$	(0.90	)	$	0.28		NA		$	0.28		NA
Adjusted Diluted EPS*	$	0.32		$	0.44		-27	%	$	0.40		-20	%

* See Tables A and B at the end of this release for reconciliation of adjusted amounts to GAAP.

“Our CRM, Neuromodulation, Vascular Access and Electrochem product line revenue were generally in line with initial expectations,” stated Thomas J. Hook, Greatbatch’s President & Chief Executive Officer. “However, our Orthopaedic sales have been impacted by reduced spending on elective procedures and increased emphasis on inventory management programs from customers amid an uncertain regulatory and economic environment, which is consistent with other orthopaedic OEM suppliers. We are pleased with the progress we have made on our consolidation and operational efficiency initiatives, which have helped mitigate the impact of this lower revenue. Our operating results continue to be positively impacted despite the reduced demand for our orthopaedic products. We remain excited about the long-term prospects for our business and will continue to focus on diversifying our revenues, deepening relationships with both current and new customers, improving operational efficiencies and continuing to invest in the development of new technologies to support future growth.”

Consolidated sales in the third quarter of 2009 were $121.5 million compared to $136.2 million in the comparable 2008 period and $134.7 million for the second quarter of 2009. As expected, Cardiac Rhythm Management (“CRM”) and Neuromodulation organic revenue growth moderated during the quarter while Orthopaedic and Electrochem revenue continued to be impacted by an overall market slowdown.

Gross profit as a percentage of revenue for the 2009 third quarter improved to 32.2%, compared to 30.6% for the third quarter 2008. This improvement was due to a higher mix of CRM/Neuromodulation revenue in the current quarter as well as the impact of consolidation initiatives completed over the past year.

Selling, general and administrative expenses of $15.8 million for the third quarter of 2009 were consistent with the same period of 2008 as normal inflationary cost increases were offset by savings from our various consolidation initiatives and lower performance based compensation.

Net research, development and engineering costs for the 2009 third quarter were $9.7 million which, as expected, were up from $6.8 million in the 2008 third quarter. This increase was due to the strategic decision in 2009 to further invest resources in the development of new technologies in order to provide solutions for our customers and ultimately create long-term growth opportunities.

GAAP operating loss for the third quarter of 2009 was $23.9 million compared to income of $15.7 million in the third quarter of 2008 and income of $12.5 million in the second quarter 2009. GAAP operating results for the current quarter include a $34.5 million litigation charge related to the previously disclosed jury verdict in the Electrochem litigation, which includes interest on the award and estimated attorneys’ fees and costs.

Adjusted operating income was $13.6 million, or 11.2% of sales, in the third quarter 2009, compared to $19.3 million, or 14.2% of sales, for the comparable 2008 period and $14.9 million or 11.1% of sales in the second quarter 2009. This decrease is primarily due to the decrease in revenue and increase in R&D investment as discussed above. Adjusted amounts presented in this release exclude the impact of acquisition-related charges, as well as facility consolidation, manufacturing transfer, system integration expenses and litigation charges.

The adjusted and GAAP effective tax rates for the third quarter 2009 were 30.2% and 27.9%, respectively, compared to 36.5% and 41.3%, respectively, for the third quarter in 2008. The 2009 third quarter adjusted and GAAP effective tax rates include the favorable impact of the resolution of tax audits and the lapse of statutes of limitation on certain tax items during the quarter.

GAAP EPS decreased to a $0.90 loss per share in the third quarter 2009, compared to income of $0.28 per share for both the third quarter 2008 and second quarter 2009. Adjusted EPS decreased to $0.32 per share in the third quarter 2009 from $0.44 per share in the third quarter 2008 and $0.40 for the second quarter of 2009. Prior year amounts have been retroactively adjusted, as required by GAAP, to reflect the change in accounting related to convertible debentures adopted in 2009.

Cash flows from operations for the third quarter of 2009 of approximately $29 million were used to support normal capital expenditures and to pay down our line of credit by $14 million, or 12% of the outstanding balance. For the first nine months of 2009, cash flows from operations were approximately $50 million and the Company has repaid $25 million, or 19% of its line of credit balance. As of October 2, 2009, the Company had $29.5 million of cash and cash equivalents and $128 million of availability under its revolving line of credit.

“During this economic downturn and challenging health care market environment, we continue to focus on the variables that are within our control,” commented Thomas J. Mazza, Senior Vice President & Chief Financial Officer. “In the third quarter we continued to take cost cutting measures to help offset the impact of our reduced revenue, continued to consolidate our Teterboro NJ facility into our Raynham MA facility, which is on schedule for completion in the fourth quarter, and converted two facilities to our ERP platform to further streamline operations. Additionally, we continued to invest in the development of new technologies as evidenced by the increase in gross RD&E to 9% of sales. We remain confident that our continued focus on these initiatives coupled with our strong cash generation will provide significant growth opportunities once the markets recover.”

The following table summarizes the Company’s sales by major product lines for the third quarters of 2009 and 2008 (in thousands):

Product Lines	2009 3rd Qtr.		2008 3rd Qtr.		% Change		2009 2nd Qtr.		% Change
Greatbatch Medical
CRM/Neuromodulation	$	74,094	$	70,540	5	%	$	78,026	-5	%
Vascular Access		8,375		8,840	-5	%		9,152	-8	%
Orthopaedic		23,190		37,940	-39	%		31,389	-26	%
Total Greatbatch Medical		105,659		117,320	-10	%		118,567	-11	%
Electrochem		15,811		18,922	-16	%		16,158	-2	%
Total Sales	$	121,470	$	136,242	-11	%	$	134,725	-10	%

Compared to the prior year and consistent with our expectations, CRM and Neuromodulation revenue growth moderated to 5% during the third quarter compared to the same period of 2008 and is now more in line with market growth rates compared to the above-market growth rates experienced over the last several quarters. More specifically, increased growth in medical batteries due to market growth and customer market share shifts was partially offset by a decrease in capacitor sales due to inventory adjustments made by OEM customers during the quarter. In comparison to the second quarter of 2009, CRM and Neuromodulation revenue declined 5% due to the timing of customer product launches. CRM and Neuromodulation revenue can vary significantly from quarter to quarter based upon the timing of customer product launches, customer outsourcing decisions, changes in customer market share mix and customer inventory adjustments, as well as marketplace field actions.

Third quarter revenues for the Vascular Access product line were $8.4 million, compared to the prior year quarter revenues of $8.8 million and sequential quarter revenue of $9.2 million. These decreases were primarily due to lower introducer sales as a result of customer inventory adjustments.

Orthopaedic product line revenues were $23.2 million for the quarter, compared to $37.9 million for third quarter 2008 and $31.4 million for the 2009 second quarter. Current quarter revenues include the impact of reduced spending on elective procedures and increased emphasis on inventory management programs from customers as a result of the uncertain economic and regulatory environment and are consistent with other orthopaedic OEM suppliers. Foreign currency exchange rate fluctuations had a minimal impact on revenue during the quarter in comparison to the prior year. We believe that year-over-year comparisons in orthopaedic revenues will continue to be challenging for the remainder of 2009. We continue to streamline and invest in our orthopaedic operations which we believe present significant opportunities.

Third quarter 2009 sales for the Electrochem business segment were $15.8 million, compared to $18.9 million in the third quarter 2008 and $16.2 million in the sequential quarter. This decrease is primarily related to the slowdown in the Energy and Portable Medical markets, which caused customers to reduce inventory levels and push back projects. We continue to actively manage our business so that we will be better prepared to meet the needs of our customers once the markets recover. Given the reduced rate of Electrochem revenue decline during the quarter, the markets appear to have stabilized. However, we do not foresee significant market growth over the next few quarters.

Based upon our third quarter results and lower demand expectations from our orthopaedic product line for the remainder of the year, we now anticipate revenue to be between $520 million and $535 million for 2009. Despite this lower revenue, we still believe our adjusted operating income for the full year 2009 will be in line with our previously provided guidance of 11.0% to 13.0% of sales due to our on-going consolidation and cost-cutting initiatives. Note that the fourth quarter of 2008 included 14 weeks compared to the fourth quarter of 2009, which will have 13 weeks due to our 52/53 week convention. We remain focused on our long-term strategic objective of growing revenue faster than our markets through diversifying our revenue base, leading innovation, and providing customers with the technology solutions that they need to be successful.

The Company will host a conference call on Friday November 6, 2009 at 8:00 a.m. E.S.T. to discuss these results. The scheduled conference call will be webcast live and is accessible through the Company’s website at www.greatbatch.com. An audio replay will also be available beginning from 11:00 a.m. E.S.T. on November 6, 2009 until November 13, 2009. To access the replay, dial 888-286-8010 (U.S.) or 617-801-6888 (International) and enter the passcode 32334328.

Greatbatch, Inc. (NYSE:GB) provides top-quality technologies to industries that depend on reliable, long lasting performance through its brands Greatbatch Medical and Electrochem. Greatbatch Medical develops and manufactures critical technologies used in medical devices for the cardiac rhythm management, neuromodulation, vascular access and orthopaedic markets. Electrochem designs and manufactures battery and wireless sensing technologies for high-end niche applications in the Energy, Military, Portable Medical, and other markets. Additional information about the Company is available at www.greatbatch.com.

In addition to our results reported in accordance with GAAP, we provide adjusted operating income & margin, adjusted net income and adjusted earnings per diluted share. These adjusted amounts consist of GAAP amounts excluding (i) acquisition-related charges, (ii) facility consolidation, manufacturing transfer and system integration charges, (iii) asset disposition and other charges, (iv) litigation charges and (v) the income tax (benefit) related to these adjustments. Adjusted earnings per diluted share is calculated by dividing adjusted net income for diluted earnings per share by diluted weighted average shares outstanding. We believe that the presentation of adjusted operating income & margin, adjusted net income and adjusted earnings per share provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

Some of the statements in this press release, including the information provided under the caption “Financial Guidance,” and other written and oral statements made from time to time by the Company and its representatives are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and involve a number of risks and uncertainties. These statements can be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” or the negative of these terms or other comparable terminology. These statements are based on the Company’s current expectations. The Company’s actual results could differ materially from those stated or implied in such forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements include, among others, the following matters affecting the Company: our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement our cost reduction and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate the acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our inability to obtain licenses to key technology; regulatory changes or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company and other risks and uncertainties described in the Company’s Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking information in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.


Table A: Operating Income (Loss) Reconciliation (in thousands):

	2009 3rd Qtr.			2008 3rd Qtr.			2009 YTD			2008 YTD
Operating income (loss) as reported:	$	(23,933	)	$	15,714		$	3,335		$	22,926
In-process research and development		-			-			-			2,240
Acquisition charges (inventory step-up)		-			-			-			6,422
Sub-total		(23,933	)		15,714			3,335			31,588
Adjustments:
Litigation charge		34,500			-			34,500			-
Consolidation costs		1,449			1,657			4,926			3,626
Integration expenses		1,196			1,812			2,776			3,876
Asset dispositions & other		434			96			604			(28	)
Operating income – adjusted	$	13,646		$	19,279		$	46,141		$	39,062
Operating margin – adjusted		11.2	%		14.2	%		11.7	%		9.8	%

Table B: Net Income (Loss) & EPS Reconciliation (in thousands, except per share amounts):

	2009 3rd Qtr.			2008 3rd Qtr.		2009 YTD			2008 YTD
Income (loss) before taxes as reported:	$	(28,694	)	$	11,109	$	(10,821	)	$	10,238
In-process research and development		-			-		-			2,240
Acquisition charges (inventory step-up)		-			-		-			6,422
Sub-total		(28,694	)		11,109		(10,821	)		18,900
Adjustments:
Litigation charge		34,500			-		34,500			-
Consolidation costs		1,449			1,657		4,926			3,626
Integration expenses		1,196			1,812		2,776			3,876
Asset dispositions & other		434			96		604			(28	)
Sub-total		8,885			14,674		31,985			26,374

Convertible debt accounting change		1,844			1,713		5,432			5,040
Adjusted income before taxes		10,729			16,387		37,417			31,414
Adjusted provision for income taxes		3,237			5,981		10,968			10,355
Adjusted net income	$	7,492		$	10,406	$	26,449		$	21,059
Adjusted diluted EPS	$	0.32		$	0.44	$	1.12		$	0.91
Number of shares (thousands)		23,900			24,000		23,900			24,000

Note:	1)	Adjustments to 2008 were made based on the expected full year adjusted effective tax rate of 34.0% which includes the impact of IPR&D charges which are not deductible for tax purposes.
	2)	Adjustments to 2009 were made based on the expected full year adjusted effective tax rate of 31.0% which includes the impact of discrete items realized in 2009.
	3)	Prior year amounts have been retroactively adjusted, as required by GAAP, to reflect the change in accounting related to convertible debentures adopted in 2009.

GREATBATCH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - Unaudited
(In thousands except per share amounts)

	Three months ended						Nine months ended
	October 2, 2009			September 26, 2008 (1)			October 2, 2009			September 26, 2008 (1)

Sales	$	121,470		$	136,242		$	396,013		$	400,044
Cost of sales		82,333			94,489			271,240			290,997
Gross profit		39,137			41,753			124,773			109,047
Operating expenses:
Selling, general and administrative expenses		15,790			15,681			52,362			52,685
Research, development and engineering costs, net		9,701			6,793			26,270			23,722
Acquired in-process research and development		-			-			-			2,240
Litigation charge		34,500			-			34,500			-
Other operating expense, net		3,079			3,565			8,306			7,474
Total operating expenses		63,070			26,039			121,438			86,121
Operating income (loss)		(23,933	)		15,714			3,335			22,926
Interest expense		4,895			4,981			14,714			14,948
Interest income		(22	)		(142	)		(49	)		(663	)
Other income, net		(112	)		(234	)		(509	)		(1,597	)
Income (loss) before provision (benefit) for income taxes		(28,694	)		11,109			(10,821	)		10,238
Provision (benefit) for income taxes		(8,001	)		4,593			(3,354	)		3,454
Net income (loss)	$	(20,693	)	$	6,516		$	(7,467	)	$	6,784

Earnings (loss) per share:
Basic	$	(0.90	)	$	0.29		$	(0.33	)	$	0.30
Diluted	$	(0.90	)	$	0.28		$	(0.33	)	$	0.30

Weighted average shares outstanding:
Basic		23,000			22,600			22,900			22,500
Diluted		23,000			24,100			22,900			22,700

GREATBATCH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS - Unaudited
(In thousands)

ASSETS	October 2,		January 2,
	2009		2009 (1)
Current assets:
Cash and cash equivalents	$	29,545	$	22,063
Accounts receivable, net		76,637		86,364
Inventories, net		115,761		112,304
Deferred income taxes		15,033		8,086
Prepaid expenses and other current assets		10,843		6,754
Total current assets		247,819		235,571

Property, plant, and equipment, net		157,000		166,668
Intangible assets, net		120,682		126,389
Goodwill		303,994		302,221
Deferred income taxes		2,413		1,942
Other assets		15,453		15,242
Total assets	$	847,361	$	848,033

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	28,804	$	48,727
Income taxes payable		2,570		4,128
Current portion of long-term debt		30,450		-
Accrued expenses and other current liabilities		74,857		40,497
Total current liabilities		136,681		93,352

Long-term debt		265,656		314,384
Deferred income taxes		58,251		57,905
Other long term liabilities		6,831		7,601
Total liabilities		467,419		473,242
Stockholders' equity:
Preferred stock		-		-
Common stock		23		23
Additional paid-in capital		290,488		283,322
Treasury stock		-		(741	)
Retained earnings		87,796		95,263
Accumulated other comprehensive gain (loss)		1,635		(3,076	)
Total stockholders’ equity		379,942		374,791
Total liabilities and stockholders' equity	$	847,361	$	848,033

CONTACT:
Greatbatch, Inc.
Marco Benedetti, Corporate Controller & Treasurer
716-759-5856